论文部分内容阅读
研究拉米夫定联合苷必妥治疗慢性乙型肝炎病人的近期疗效和安全性。选择 16例慢性乙型肝炎患者用拉米夫定 (10 0mg/d)和苷必妥 (1mg/d)治疗为观察组 ,选择 15例患者单独服用拉米夫定 (10 0mg/d)作对照 ,共治疗 12周。疗效评估包括肝功能和HBV复制指标。治疗 12周疗程结束时 ,血清HBVDNA阴转率在两组间差异无显著性 (10 0 %对 80 0 % ,P >0 0 5 ) ,观察组HBeAg阴转率显著高于对照组 (87 5 %对 2 6 7% ,P <0 0 1) ,HBeAg血清转换率在两组间差异有显著性 (78 6 %对 2 5 0 % ,P <0 0 5 ) ,观察组ALT的复常率显著高于对照组 (10 0 0 %对6 6 7% ,P <0 0 5 )。未发生不良反应。拉米夫定联合苷必妥治疗慢性乙型肝炎的近期疗效肯定 ,安全性好
To study the short-term curative effect and safety of lamivudine and glycosides in treating chronic hepatitis B patients. Sixteen patients with chronic hepatitis B were treated with lamivudine (10 mg / d) and glycyrrhizin (1 mg / d) as observation group, and 15 patients were given lamivudine alone (10 mg / d) Control, a total of 12 weeks of treatment. Efficacy assessments include liver function and HBV replication markers. At the end of the 12-week course of treatment, the negative rate of serum HBVDNA was not significantly different between the two groups (10 0% vs 80 0%, P 0 05), and the HBeAg negative rate in the observation group was significantly higher than that in the control group % Vs 26.7%, P <0.01), the HBeAg seroconversion rate was significantly different between the two groups (78 6% vs 25 0%, P 0 05). The normalization rate of ALT in the observation group Significantly higher than the control group (100% vs 667%, P <0 05). No adverse reactions. Lamivudine combined glycosides of glyburide for the treatment of chronic hepatitis B, the recent efficacy of certain, good safety